New obesity drug XW003 takes on semaglutide in Head-to-Head trial
NCT ID NCT07073417
First seen Apr 15, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests a new drug called XW003 against an existing weight-loss drug, semaglutide, in 163 Chinese adults with obesity. Participants must have a BMI of 30 or higher and a large waist size. The main goal is to see how much weight they lose and how safe the drugs are. This is a phase 2 trial, meaning it's still early in testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.